MedPath

Researchers Assess the Role of Vitamin K2 in Managing Nocturnal Leg Cramps

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cenerimod Shows Promise in Treating Systemic Lupus Erythematosus: Phase 2b CARE Study Results

The Phase 2b CARE study demonstrated that cenerimod, a selective S1P1 receptor modulator, led to clinically meaningful improvements in adults with moderate-to-severe SLE.
Patients treated with cenerimod 4 mg showed significant and lasting improvements in SLE disease activity compared to placebo, alongside stable background therapy.

Clinical Trials Advance for Potential Kennedy's Disease Therapies

Structured exercise programs are under Phase 2 trials to improve muscle strength and function in Kennedy's disease patients.
Clenbuterol, an asthma drug, is in Phase 2 trials to assess its ability to enhance muscle stamina and quality of life.

TENS Device Shows Promise in Alleviating Long COVID Symptoms

A new study suggests that Transcutaneous Electrical Nerve Stimulation (TENS) may reduce pain and fatigue associated with long COVID.
Participants using the TENS device reported a 26% reduction in pain and an 8% improvement in walking ability compared to the placebo group.

Semaglutide Shows Promise in Reducing Knee Pain in Osteoarthritis Patients

A recent study in the New England Journal of Medicine suggests semaglutide significantly reduces knee pain in obese patients with osteoarthritis.
Participants taking semaglutide experienced a 14-point greater reduction in pain on a 0-100 scale compared to those on a placebo.

Semaglutide Reduces Knee Osteoarthritis Pain and Improves Function in Obese Patients

Semaglutide significantly reduced knee osteoarthritis pain and body weight in obese patients, as shown in the STEP 9 trial.
The study demonstrated that semaglutide led to greater improvements in pain-related endpoints compared to placebo.

Semaglutide Shows Promise in Relieving Osteoarthritis Pain

A recent study reveals semaglutide, found in Ozempic and Wegovy, significantly reduces knee osteoarthritis pain and improves mobility.
Participants experienced nearly a 50% decrease in pain, with some no longer meeting enrollment criteria due to improved conditions.

Semaglutide Shows Promise in Easing Knee Arthritis Pain in Obese Patients

Semaglutide, the active agent in Ozempic and Wegovy, led to a significant weight loss of nearly 14% in obese patients after 68 weeks, compared to 3% in the placebo group.
The weight loss from semaglutide resulted in a notable decrease in knee pain and improved knee function among patients with obesity-related knee osteoarthritis.

Vitamin K2 Shows Promise in Reducing Nocturnal Leg Cramps in Elderly

A randomized clinical trial found that vitamin K2 supplementation significantly reduces the frequency of nocturnal leg cramps (NLCs) in older adults.
Participants taking vitamin K2 experienced a notable decrease in the severity and duration of NLCs compared to those receiving a placebo.

Multidisciplinary Therapy Improves Outcomes in Functional Movement Disorders

A randomized clinical trial demonstrates that integrating physiotherapy and cognitive-behavioral therapy improves symptoms in patients with functional movement disorders.
Patients receiving the multidisciplinary approach showed a 50% reduction in motor symptom severity at a 5-month follow-up compared to the control group.

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS

Immunic, Inc. showcased significant data on vidofludimus calcium's therapeutic potential in multiple sclerosis at the 40th Congress of ECTRIMS, highlighting its neuroprotective and anti-inflammatory effects.

Reference News

[1]
Researchers Assess the Role of Vitamin K2 in Managing Nocturnal Leg Cramps
pharmacytimes.com · Nov 10, 2024

A randomized clinical trial published in JAMA Internal Medicine found vitamin K2 may reduce nocturnal leg cramps (NLCs) ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy